Penetrance of LFS is variable, but it is estimated that germline loss-of-function mutations in TP53 can be associated with up to a 70% lifetime risk of cancer in men and up to a 90% lifetime risk of cancer in women, with a large number of patients presenting with their first malignancy in childhood, adolescence and young adulthood [5,6]. The gene discussed is TP53; the disease is cancer.